Q2 2026 Neogenomics Inc Earnings Call Transcript
Key Points
- NeoGenomics Inc (NEO) reported a strong 11% year-over-year revenue growth, reaching $201.7 million, surpassing their guidance.
- The clinical business showed robust performance with a 14% increase in revenue, driven by a 12% rise in average unit price (AUP) and a 2% increase in test volumes.
- The Next-Generation Sequencing (NGS) segment experienced a 26% revenue growth, indicating strong demand and market penetration.
- The company achieved significant margin improvement, with adjusted gross margin expanding by 260 basis points year over year.
- NeoGenomics Inc (NEO) raised its full-year 2026 revenue guidance, reflecting confidence in continued growth and performance.
- The nonclinical business, particularly the pharma segment, underperformed with a 26% decline in revenue, impacting overall growth.
- Despite strong clinical performance, the overall volume growth was slightly below expectations due to the exit from a high-volume, low-value contract.
- The company faces challenges in the pharma business, which accounts for about 5% of total revenue, and is working to return it to growth by 2027.
- There is uncertainty around the timing and process of obtaining private insurer coverage for new tests, which could impact future revenue streams.
- NeoGenomics Inc (NEO) is experiencing increased interest expenses due to a 50 basis point rise in the interest rate on new convertible senior notes.
Good afternoon and welcome to the NeoGenomics second-quarter 2026 financial results call. (Operator Instructions) Please be advised that today's conference is being recorded.
I will now turn the call over to Abhishek Jain, Chief Financial Officer.
Before we begin, I would like to introduce Andrew Brackmann, who recently joined NeoGenomics as our new Vice President of Investor Relations. Andrew spent nearly a decade in sell-side equity research covering the diagnostic sector. He also covered NeoGenomics directly, giving him a deep understanding of both the company and its competitive landscape.
Beyond his analytical depth, Andrew is known for building genuine, long-term relationships with the people he works with. We're excited to have Andrew on board to lead and shape our Investor Relations strategy and deepen our relationships across the investor and analyst community.
Now let me turn the call over to Andrew to get us started. Andrew.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
